Granulocyte colony-stimulating factors: finding the right indication
Authors:
- Gary H LymanGLGary H Lyman
- Michelle ShayneMSMichelle Shayne
- 1 July 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 19 (4) , 299-307
Abstract
Neutropenic complications including febrile neutropenia represent major dose-limiting toxicities of cancer chemotherapy. Recommendations for the use of recombinant myeloid growth factors to reduce the risk of neutropenic complications and sustain dose intensity continue to evolve. Several randomized controlled trials and meta-analyses have confirmed that the myeloid growth factors reduce the risk of neutropenic complications and may facilitate delivered dose intensity in patients receiving cancer chemotherapy. Older age and certain comorbidities significantly increase the risk of febrile neutropenia and its consequences. Three new clinical practice guidelines for the use of the myeloid growth factors have been published by major professional oncology organizations including the American Society of Clinical Oncology, the European Organization for Research and Treatment of Cancer and the National Comprehensive Cancer Network. The recommendations and evidence basis for these guidelines are presented here. All three new or updated guidelines recommend prophylactic use of the myeloid growth factors in cancer patients receiving chemotherapy at 20% or greater risk of febrile neutropenia and in those with important variables that increase individual risk of neutropenic complications. Consistent clinical practice guidelines based on multiple randomized control trials and meta-analyses should further guide the appropriate and cost-effective use of these agents.Keywords
This publication has 48 references indexed in Scilit:
- Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile NeutropeniaPharmacoEconomics, 2007
- 30 A risk model for first cycle neutropenic events in older cancer patients receiving systemic chemotherapyCritical Reviews in Oncology/Hematology, 2006
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEuropean Journal of Cancer, 2006
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapyBreast Cancer Research and Treatment, 2006
- Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of actionExpert Opinion on Biological Therapy, 2005
- Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled TrialsJournal of Clinical Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsNew England Journal of Medicine, 2001